BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression

Pharmacogenetics and Genomics

Volumn 23, Issue 6, 2013, Pages 301-313

  Murphy, Greer M ^a   Sarginson, Jane E ^a   Ryan, Heather S ^a   O'Hara, Ruth ^a   Schatzberg, Alan F ^a   Lazzeroni, Laura C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Aged; Antidepressive agents; Brain derived neurotrophic factor; Cyclic AMP responsive element binding protein 1; Pharmacogenetics

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; METHIONINE; MIRTAZAPINE; PAROXETINE; TYROSINE KINASE RECEPTOR;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; GERIATRICS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANIMALIA;

EID: 84879132439     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328360b175     Document Type: Article

References (57)

1. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982; 1:549-553.
2. Davies AM, Thoenen H, Barde YA. The response of chick sensory neurons to brain-derived neurotrophic factor. J Neurosci 1986; 6:1897-1904.
3. Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 2010; 70:271-288.
4. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539-7547.
5. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21:679-682.
6. Siuciak JA, Lewis DR,Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56:131-137.
7. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22:3251-3261.
8. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010; 35:2378-2391.
9. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11:1169-1180.
10. Pencea V, Bingaman KD,Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21:6706-6717.
11. Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci USA 2008; 105:15570-15575.
12. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005; 25:1089-1094.
13. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007; 90:397-406.
14. Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol 2012; 30:453-459.
15. Chen ZY, Bath K, McEwen B, Hempstead B, Lee F. Impact of genetic variant BDNF (Val66Met) on brain structure and function. Novartis Found Symp 2008; 289:180-188, discussion 188-195.
16. Rybakowski JK. BDNF gene: Functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008; 9:1589-1593.
17. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci 2004; 8:325-335.
18. Lencz T, Lipsky RH, DeRosse P, Burdick KE, Kane JM, Malhotra AK. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry 2009; 194:313-318.
19. Tsai SJ, Hong CJ, Liou YJ. Effects of BDNF polymorphisms on antidepressant action. Psychiatry Investig 2010; 7:236-242.
20. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, et al. Brain-derived neurotrophic factor gene polymorphisms: Influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 2011; 26:1-10.
21. Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE Jr, et al. BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord 2010; 125: 262-268.
22. Taylor WD, McQuoid DR, Ashley-Koch A, Macfall JR, Bridgers J, Krishnan RR, Steffens DC. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J 2011; 11:146-154.
23. Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci 2012; 32:4092-4101.
24. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23:6690-6694.
25. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112:257-269.
26. Goldberg TE, Iudicello J, Russo C, Elvevag B, Straub R, Egan MF,Weinberger DR. BDNF Val66Met polymorphism significantly affects d0 in verbal recognition memory at short and long delays. Biol Psychol 2008; 77:20-24.
27. Dincheva I, Glatt CE, Lee FS. Impact of the BDNF Val66Met polymorphism on cognition: Implications for behavioral genetics. Neuroscientist 2012; 18:439-451.
28. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49:753-762.
29. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2010; 107:22687-22692.
30. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14:1105-1118.
31. Lin E, Hong CJ, Hwang JP, Liou YJ, Yang CH, Cheng D, Tsai SJ. Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res 2009; 12:387-393.
32. Juhasz G, Dunham JS, McKie S, Thomas E, Downey D, Chase D, et al. The CREB1-BDNF-NTRK2 pathway in depression: Multiple gene-cognition-environment interactions. Biol Psychiatry 2011; 69:762-771.
33. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10:541-550.
34. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160:1830-1835.
35. Folstein MF, Folstein SE, McHugh PR.'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
36. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296.
37. Pettersson FH, Anderson CA, Clarke GM, Barrett JC, Cardon LR, Morris AP, Zondervan KT. Marker selection for genetic case-control association studies. Nat Protoc 2009; 4:743-752.
38. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449:851-861.
39. De Bakker PI, Graham RR, Altshuler D, Henderson BE, Haiman CA. Transferability of tag SNPs to capture common genetic variation in DNA repair genes across multiple populations. Pac Symp Biocomput 2006; 478-486.
40. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007; 31:383-395.
41. Ballard DH, Cho J, Zhao H. Comparisons of multi-marker association methods to detect association between a candidate region and disease. Genet Epidemiol 2010; 34:201-212.
42. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry 2003; 54:665-673.
43. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006; 1118:176-182.
44. Licinio J, Dong C,Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66:488-497.
45. Chi MH, Chang HH, Lee SY, Lee IH, Gean PW, Yang YK, et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord 2010; 126:430-435.
46. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314:140-143.
47. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59:1116-1127.
48. Zhang J, Rowe WL, Clark AG, Buetow KH. Genomewide distribution of highfrequency, completely mismatching SNP haplotype pairs observed to be common across human populations. Am J Hum Genet 2003; 73:1073-1081.
49. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64:689-697.
50. Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 2011; 128:56-63.
51. Utge S, Soronen P, Partonen T, Loukola A, Kronholm E, Pirkola S, et al. A population-based association study of candidate genes for depression and sleep disturbance. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:468-476.
52. Chen MJ, Russo-Neustadt AA. Running exercise-induced up-regulation of hippocampal brain-derived neurotrophic factor is CREB-dependent. Hippocampus 2009; 19:962-972.
53. Kang RH, Chang HS,Wong ML, Choi MJ, Park JY, Lee HY, et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol 2010; 24:1755-1763.
54. Zhang Y, Gu F, Chen J, Dong W. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res 2010; 1366:141-148.
55. Nemeroff CB, Owens MJ. Neuropharmacology of paroxetine. Psychopharmacol Bull 2003; 37 (Suppl 1):8-18.
56. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7:249-264.
57. Wilkie MJ, Smith D, Reid IC, Day RK, Matthews K,Wolf CR, et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 2007; 17:207-215.